Centene and the Limits of Discipline
By RaeAnn, Founder and Chief Executive Officer, HLTHWORKS
The number that reframes it
In fiscal year 2025 Centene grew total revenue 19.4 percent, to 194.8 billion dollars, and posted a net loss of 6.7 billion dollars against net income of 3.3 billion dollars the year before.
Those two facts do not usually appear together, and the reconciliation matters more than either number. The loss was driven by a non-cash goodwill impairment of 6.723 billion dollars recorded in the third quarter, alongside a further 513 million dollar impairment tied to a pending divestiture. Strip the impairment out and the company would have posted a small profit. Operating cash flow for the year was 5.1 billion dollars. Adjusted diluted earnings per share were 2.08 dollars.
So nothing left the building. What happened is that the balance sheet was rewritten to match a market value that had collapsed.
The company was explicit about why. It performed the impairment analysis because of market conditions in July of 2025, specifically the One Big Beautiful Bill Act and the decline in its own stock price. The Act reduces federal Medicaid spending by more than nine hundred billion dollars over ten years, imposes work requirements expected to remove roughly five million people from the program, and ends the enhanced Marketplace subsidies. Centene’s stock hit its lowest point in a decade that month.
In 2025, Medicaid accounted for 57 percent of external revenues, Medicare 19 percent, and Commercial 21 percent, and the Commercial segment is predominantly Marketplace rather than employer business. Centene is the largest Medicaid insurer in the country, the largest Marketplace insurer, and the largest standalone Medicare Part D sponsor.
So the hole was not operational. It was legislated. That distinction is the whole article, and it is why this case is more useful to an operator than a conventional turnaround story. Most turnaround analysis assumes the problem is inside the building. This one is about what discipline can and cannot do when the problem is written into statute.
She had already run the playbook
The uncomfortable part of the record is that Sarah London did the work early.
London joined Centene in 2020 and was named Chief Executive Officer in March of 2022, after Michael Neidorff took a medical leave of absence the month before. By February of 2023 she was able to tell investors that the company had divested seven businesses since late 2021 and reduced its real estate footprint by 70 percent.
The divestitures included PANTHERx, Magellan Rx, the prison health business, and a hospital operator in Spain. The real estate action alone carried pre-tax costs in the range of 1.5 to 1.65 billion dollars across leased and owned property, against an expected annualized reduction in leased real estate expense of 180 to 200 million dollars. London described the effect as reduced distraction, allowing the company to focus on its core business and repurchase shares.
The discipline shows in the expense line rather than in a press release. The adjusted selling, general, and administrative expense ratio was 7.4 percent for full year 2025, against 8.5 percent for 2024. That is a real structural improvement, achieved while the revenue base was under pressure.
This is the subtraction strategy the sector now discusses as though it were discovered in 2026. Centene ran it three years earlier, and ran it harder relative to its size than the larger diversified carriers did.
Then the ground moved anyway.
Nothing left the building. The balance sheet was rewritten to match a market value that had collapsed.
Then it got worse
When the enhanced Marketplace subsidies expired, Ambetter enrollment fell from roughly 5.9 million members to roughly 3.5 million. Total at-risk membership fell from just over 28 million to just under 25.9 million. Medicaid membership declined from 12.8 million to 12.1 million, and Centene lost close to 500,000 Medicaid members across 2025 alone.
The financial sequence followed. Guidance was withdrawn in July of 2025 and the company posted a 253 million dollar quarterly loss, its first in more than two years. An executive restructuring came in April of 2026. In June the company opened a voluntary separation program to most of its approximately 61,000 employees, with the stated possibility of involuntary reductions if participation fell short, and budgeted 20 to 24 million dollars in severance for the year.
London put it to employees in one sentence. When membership shifts, the organization has to shift accordingly.
It is worth being precise about what that sequence represents. This is not a company that failed to see the cost trend. It is a company that had already taken out the structural cost it could take out, and then absorbed a revenue reduction it did not control on top of that. A broad voluntary separation program at this point in a recovery is not a cost action. It is management stating that it believes the revenue base has permanently reset.
Then July 28
Centene reported second quarter 2026 net income of approximately 1.1 billion dollars, against a 253 million dollar loss in the comparable quarter. Total revenue was 53.6 billion dollars, up roughly ten percent. GAAP diluted earnings per share were 2.19 dollars and adjusted diluted earnings per share were 2.51 dollars.
The number that matters operationally is the consolidated health benefits ratio, which improved to 89.6 percent from 93.0 percent. The single sharpest segment movement was Commercial, from 90.6 percent to 79.2 percent.
The company raised total revenue guidance by six billion dollars to a range of 193.5 to 197.5 billion dollars, raised premium and service revenue guidance by two billion dollars, and lifted the adjusted diluted earnings per share floor to above 4.80 dollars. It was the second guidance increase of the year.
Read the composition rather than the headline. The revenue increase was driven by premium yield and membership growth in the prescription drug plan business, rate increases in Marketplace and Medicaid to address medical trend, Marketplace risk adjustment revenue transfer for the 2025 and 2026 benefit years, and state directed payments. It was partially offset by lower Marketplace and Medicaid membership. In other words, earnings recovered on price and mix while the book itself continued to shrink.
Why this is not the same story as Article 11
Two things separate this case from the UnitedHealth reset described in the previous article in this series.
The first is where the playbook came from. Before joining Centene in 2020, London was Chief Product Officer of Optum Analytics and a partner at Optum Ventures. The Centene turnaround is being executed by an operator trained inside the company Article 11 is about. The subtraction discipline is not a coincidence of the moment. It is a transferred method.
The second is the nature of the contraction, and it is the more important difference. UnitedHealth chose to shed roughly 2.8 million members. It selected the segments, controlled the sequence, and priced the exit. Centene was shrunk by a statute. The membership it lost was removed by eligibility and subsidy policy rather than by a portfolio decision, which means the company had no control over the timing, the geography, or the risk profile of what left.
Those are different problems even when they produce similar-looking margin restoration on a slide.
What an operator should take from this
Do the discipline early anyway.
It shortened the recovery, and the July quarter is the evidence.
Separate the resizing from the reduction.
If the revenue base has permanently reset, say so and design for it. The organizations that suffer twice are the ones that cut for a downturn and then discover they were in a reset.
Watch what recovers first.
Build the rate capability before you need it.
The health benefits ratio moved because the company got paid closer to the acuity it actually carries, across thirty state programs. That capability is built from encounter data, documentation, and credibility with the agency, and none of it can be assembled in the quarter you need it.
The line worth holding onto
Article 11 in this series described a company large enough to choose its own contraction, write off a continent, and still be the fourth largest company in the world. This one describes a company that did the same work first, more thoroughly relative to its size, and then had its revenue rewritten by a law it did not participate in drafting.
Both are now saying the same thing about 2027: margin before volume, priced market by market. The difference is that one of them arrived there by strategy and the other by necessity, and the executive who arrived there by necessity is the one who said out loud how it felt. That is not a weakness in the record. In a sector where every quarter is narrated as a headwind, it is the most credible thing anyone in this series has said.
Sources
- Second quarter 2026 results. Centene Corporation second quarter 2026 results release and Form 8-K, July 28, 2026; second quarter 2026 earnings call transcript; Reuters; Forbes; Healthcare Dive; Fierce Healthcare; Becker’s Hospital Review.
- Direct quotations and leadership profile. Fortune interview with Sarah London, 2026, including the remarks on guidance withdrawal, on the difference between running a technology business, a provider organization, and a payer, and on operating discipline at Centene; Fortune Most Powerful Women, 2026; Milken Institute speaker biography.
- Divestitures and portfolio actions. Centene press releases on the PANTHERx and Spanish and Central European transactions; Becker’s Payer Issues; St. Louis Post-Dispatch reporting on the seven divestitures and the seventy percent real estate reduction.
- Guidance withdrawal and 2025 results. Healthcare Dive reporting on the July 2025 guidance withdrawal and subsequent loss; Fortune on the full year 2025 net loss and write down.
- Workforce actions. Bloomberg Law and subsequent trade coverage of the June 2026 voluntary separation program; Centene second quarter 2026 earnings call regarding workforce and enterprise optimization.
- Medicaid rate, Part D, and product strategy. Centene second quarter 2026 earnings call regarding Medicaid rate impact, Marketplace pre tax margin outlook, risk adjustment development, and premium and service revenue drivers including prescription drug plan membership; Healthcare Dive on the appointment of a first head of ICHRA products; Milken Institute speaker biography on dual eligible and ICHRA investment; KFF snapshot of the Medicare Part D prescription drug benefit on standalone plan availability.
- Policy context. Published analysis of the One Big Beautiful Bill Act provisions affecting Medicaid spending and Marketplace eligibility.
Figures reflect company disclosures and published reporting available at the time of writing. Guidance is forward looking and subject to revision. This article is analysis provided for general informational purposes and is not investment, legal, or actuarial advice.
Also in The Standard
HLTHWORKS transforms Medicare Advantage, Commercial, and Medicaid health plans, driving efficiency in the business of health, impact in the value and quality of care delivery, and simplicity in the patient journey.
Related Posts
